|
Jun 26
|
Moderna RSV Vaccine Efficacy Sinks Over Time, CDC Documents Show
|
|
Jun 26
|
Sector Update: Health Care Stocks Lower in Afternoon Trading
|
|
Jun 26
|
Why Is Moderna Stock Trading Lower On Wednesday?
|
|
Jun 26
|
Moderna shares decline, RSV vaccine efficacy lags behind competitors
|
|
Jun 25
|
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
|
|
Jun 25
|
Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine
|
|
Jun 24
|
The FDA awarded a record number of review designations to mRNA vaccines in 2023
|
|
Jun 18
|
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
|
|
Jun 17
|
Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors
|
|
Jun 17
|
Moderna Stock (NASDAQ:MRNA): Is There Life Beyond Disease Outbreaks?
|
|
Jun 16
|
Moderna Just Gave Investors Another Reason to Buy the Stock
|
|
Jun 15
|
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
|
|
Jun 14
|
Moderna (NASDAQ:MRNA) shareholders are still up 857% over 5 years despite pulling back 6.1% in the past week
|
|
Jun 14
|
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial
|
|
Jun 13
|
Moderna says next-gen COVID shot effective in study
|
|
Jun 13
|
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
|
|
Jun 12
|
Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says
|
|
Jun 12
|
7 Struggling Stocks to Sell Before July 2024
|
|
Jun 12
|
Moderna announces positive Phase III data for Covid-19/Influenza mRNA vaccine
|
|
Jun 11
|
Moderna president: Company outlook 'stabilizing' thanks to new flu-COVID vaccine data
|